They confuse the investor by mixing calender and FY08, but it seems that they expect to close the Oncobionics aq by end of 08 F, ie mid next year. That would be a pretty sure sign that the technology works, if it does. And if it does it vastly increases the value of ANGO stock.
Without IRE, we are looking at sales up 20% and eps up 30% in FY09... say analyst averages... for GAAP earnings.
Assuming legal costs go away and are 1offs next year would be 80c, this quarter was 14c.